2013
High-dose midazolam infusion for refractory status epilepticus
Fernandez A, Lantigua H, Lesch C, Shao B, Foreman B, Schmidt JM, Hirsch LJ, Mayer SA, Claassen J. High-dose midazolam infusion for refractory status epilepticus. Neurology 2013, 82: 359-365. PMID: 24363133, PMCID: PMC3929199, DOI: 10.1212/wnl.0000000000000054.Peer-Reviewed Original ResearchConceptsHigh-dose groupRefractory status epilepticusLow-dose groupStatus epilepticusLower mortalityHigh-dose midazolam infusionLower seizure ratesStatus epilepticus onsetClass III evidenceLow-dose protocolHigher infusion ratesHospital complicationsHospital courseSeizure recurrenceBaseline characteristicsSeizure controlWithdrawal seizuresMedian timeDischarge mortalityMidazolam dosesMidazolam infusionSeizure rateWorse outcomesTreatment protocolInfusion rate
2010
Comparative Effectiveness of 10 Antiepileptic Drugs in Older Adults With Epilepsy
Arif H, Buchsbaum R, Pierro J, Whalen M, Sims J, Resor SR, Bazil CW, Hirsch LJ. Comparative Effectiveness of 10 Antiepileptic Drugs in Older Adults With Epilepsy. JAMA Neurology 2010, 67: 408-415. PMID: 20385905, DOI: 10.1001/archneurol.2010.49.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAminesAnticonvulsantsCarbamazepineCyclohexanecarboxylic AcidsDose-Response Relationship, DrugDrug ResistanceEpilepsyFemaleFructoseGabapentinGamma-Aminobutyric AcidHumansLamotrigineLevetiracetamMaleMiddle AgedOxcarbazepinePhenytoinPiracetamRetrospective StudiesTopiramateTreatment OutcomeTriazinesConceptsSeizure freedom ratesAntiepileptic drugsSeizure freedomOlder adultsOverall groupColumbia Comprehensive Epilepsy CenterAdverse effectsIntolerable adverse effectsFirst antiepileptic drugPercentage of patientsComprehensive Epilepsy CenterEffective antiepileptic drugGastrointestinal symptomsRefractory diseaseMore patientsRetrospective reviewEpilepsy centersMAIN OUTCOMEDose changesPatientsComparative effectivenessMore monthsOxcarbazepineLevetiracetamRetention rate
2008
Efficacy of Clobazam as Add-on Therapy for Refractory Epilepsy
Montenegro MA, Arif H, Nahm EA, Resor SR, Hirsch LJ. Efficacy of Clobazam as Add-on Therapy for Refractory Epilepsy. Clinical Neuropharmacology 2008, 31: 333-338. PMID: 19050410, DOI: 10.1097/wnf.0b013e31815cd960.Peer-Reviewed Original ResearchConceptsRefractory epilepsyEpilepsy centersColumbia Comprehensive Epilepsy CenterAntiepileptic drug regimenEfficacy of clobazamIntroduction of clobazamUS epilepsy centersUse of clobazamMultiple seizure typesComprehensive Epilepsy CenterAntiepileptic drug trialsPopulation of patientsAddition of clobazamMeasures of efficacyBinary logistic regressionDrug regimenSeizure freedomSeizure typesKaplan-MeierUS CentersDrug trialsPatientsUS FoodClobazamDrug Administration
2007
Effect of Age and Comedication on Levetiracetam Pharmacokinetics and Tolerability
Hirsch LJ, Arif H, Buchsbaum R, Weintraub D, Lee J, Chang JT, Resor SR, Bazil CW. Effect of Age and Comedication on Levetiracetam Pharmacokinetics and Tolerability. Epilepsia 2007, 48: 1351-1359. PMID: 17573925, DOI: 10.1111/j.1528-1167.2007.01043.x.Peer-Reviewed Original ResearchConceptsTolerability of levetiracetamLEV clearanceOlder adultsYoung adultsAdverse effectsEnzyme-inducing antiepileptic drugsOlder groupSame serum levelsCommon adverse effectsSubgroup of patientsGroup of patientsSpecific adverse effectsBehavioral side effectsOne-year retentionLevetiracetam pharmacokineticsEffect of ageOlder patientsYounger patientsApparent clearanceSerum levelsAntiepileptic drugsLEV useAdult outpatientsLow doseLevetiracetamA Randomized, Double‐Blind, Placebo‐Controlled Trial of Donepezil to Improve Memory in Epilepsy
Hamberger MJ, Palmese CA, Scarmeas N, Weintraub D, Choi H, Hirsch LJ. A Randomized, Double‐Blind, Placebo‐Controlled Trial of Donepezil to Improve Memory in Epilepsy. Epilepsia 2007, 48: 1283-1291. PMID: 17484756, DOI: 10.1111/j.1528-1167.2007.01114.x.Peer-Reviewed Original ResearchMeSH KeywordsCholinesterase InhibitorsCognition DisordersCross-Over StudiesDonepezilDose-Response Relationship, DrugDouble-Blind MethodEpilepsyHealth StatusHumansIndansMemory DisordersNeuropsychological TestsPiperidinesPlacebosQuality of LifeSeverity of Illness IndexSocial AdjustmentTreatment OutcomeConceptsSubjective memory difficultyMemory difficultiesPsychological functionsCognitive functionSocial functioningSelf-rated memoryAssessment of memorySubjective memory complaintsTrial of donepezilDonepezil treatmentSubjective memoryMemory complaintsSelf-rated qualityMemoryTreatment phaseEpilepsy patientsMoodFunctioningParticular epilepsy syndromesGroup resultsDonepezilAcetylcholinesterase inhibitorsDifficultiesPlacebo treatmentSeizure frequency
2006
Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders
Malik S, Arif H, Hirsch LJ. Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders. Expert Review Of Neurotherapeutics 2006, 6: 1609-1627. PMID: 17144777, DOI: 10.1586/14737175.6.11.1609.Peer-Reviewed Original ResearchConceptsBroad-spectrum antiepileptic drugBipolar disorder type ILennox-Gastaut syndromeTreatment of epilepsySerious skin rashesTreatment of womenFavorable pharmacokinetic propertiesConcomitant medicationsNeuropathic painElderly patientsSkin rashAdjunctive treatmentDose adjustmentGeneralized seizuresPartial seizuresAntiepileptic drugsSlow titrationNeurological conditionsPsychiatric disordersAdult populationLamotriginePharmacokinetic propertiesSmall riskPreliminary dataEpilepsy
2004
Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy
Hirsch LJ, Weintraub D, Du Y, Buchsbaum R, Spencer HT, Hager M, Straka T, Bazil CW, Adams DJ, Resor SR, Morrell MJ. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 2004, 63: 1022-1026. PMID: 15452293, DOI: 10.1212/01.wnl.0000138424.33979.0c.Peer-Reviewed Original ResearchMeSH KeywordsAnticonvulsantsDose-Response Relationship, DrugDrug EruptionsDrug InteractionsDrug Therapy, CombinationEpilepsyFemaleGastrointestinal DiseasesHeadacheHumansLamotrigineMaleMental DisordersNervous System DiseasesRetrospective StudiesSleep Initiation and Maintenance DisordersTriazinesValproic AcidConceptsLamotrigine serum concentrationsSpecific side effectsAntiepileptic drugsSide effectsSerum levelsLTG levelsSerum concentrationsColumbia Comprehensive Epilepsy CenterConcomitant antiepileptic drugsLTG serum levelsComprehensive Epilepsy CenterRates of toxicityDuration of useInitial target rangeAED regimensRefractory patientsToxic regimenConcurrent medicationsSeizure freedomAdditional efficacyClinical toxicityEpilepsy centersLTG concentrationsClinical trialsDose changes